Kaerus Bioscience's lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS) ...Middle East

FDA's two designations demonstrate KER-0193's potential as a treatment for FXS Follows the successful completion of Phase 1 clinical trial Fragile X syndrome is the most common cause of inherited autism LONDON, May 14, 2025 /PRNewswire/ -- Kaerus Bioscience ("Kaerus" or "the Company"), a...

Read More Details
Finally We wish PressBee provided you with enough information of ( Kaerus Bioscience's lead candidate KER-0193 granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA for treatment of Fragile X syndrome (FXS) )

Also on site :

• Rock Legend Shares Bold Message About L.A. Protests
• ‘Mormon Wives’ Star Taylor Frankie Paul Posts About ‘Betrayal’ Ahead of Season 2, Part 2 Drop
• AriZona's 'Perfect' New Flavor Sends Fans Racing to the Store